|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Walter V. Klemp||Founder, Chairman, Pres & CEO||891,66k||N/D||1960|
|Mr. Jonathan P. Foster CPA||Exec. VP & CFO||611,2k||N/D||1964|
|Dr. Donald H. Picker Ph.D.||Chief Scientific Officer||479,87k||N/D||1946|
|Dr. Waldemar Priebe Ph.D.||Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board||N/D||N/D||N/D|
|Dr. Robert C. Shepard FACP, M.D., F.A.C.P.||Chief Medical Officer of Annamycin||N/D||N/D||1952|
|Dr. John Paul Waymack M.D., Sc.D.||Sr. Chief Medical Officer||N/D||N/D||1952|
|Dr. Sandra L. Silberman M.D., Ph.D.||Chief Medical Officer of New Products||N/D||N/D||1955|
|Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.||European Chief Medical Officer||N/D||N/D||N/D|
|Ms. Jacqueline Northcut||Consultant||N/D||N/D||1962|
|Mr. Louis Ploth Jr.||Independent Advisor||N/D||N/D||1954|
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
L'ISS Governance QualityScore di Moleculin Biotech, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.